Data supporting the physiological effects of cannabidiol (CBD) ingestion in humans are conflicting. Differences between CBD preparations and bioavailability may contribute to these discrepancies. Further, an influence of body composition on CBD bioavailability is feasible, but currently undocumented. The aims of this study were to: (1) compare the pharmacokinetics of five oral CBD preparations over 4 h; (2) examine the relationship between body composition and CBD pharmacokinetics; and, (3) explore the influence of CBD on heart rate variability. In total, five preparations of CBD, standardized to 30 mg, were orally administered to 15 healthy men and women (21–62 years) in a randomized, crossover design. Prior to and 60 min following CBD ingestion, heart rate variability was determined. Body composition was assessed using dual energy X-ray absorptiometry. Peak circulating CBD concentration, time to peak concentration, and area under the curve was superior in a preparation comprising 5% CBD concentration liquid. Fat free mass was a significant predictor (R2 = 0.365, p = 0.017) of time to peak concentration for this preparation. Several heart rate variability parameters, including peak frequency of the high frequency band, were favorably, but modestly modified following CBD ingestion. These data confirm an influence of CBD preparation and body composition on CBD bioavailability, and suggest that acute CBD ingestion may have a modest influence on autonomic regulation of heart rate.
The purpose of the study was to describe and compare the pharmacokinetics of five commercial edible marijuana products, determine the influence of body composition on pharmacokinetics, and, in light of epidemiology suggesting marijuana may offer diabetes protection, explore the influence of edible marijuana on glucose tolerance. Seven regular users of marijuana self-administered five edible products in a randomized crossover design; each product contained 10 mg of delta-9-tetrahydrocannabinol (THC). Thirty minutes following marijuana ingestion, participants imbibed a 75 g glucose beverage. Time-to-peak plasma THC concentration ranged between 35 and 90 min; maximal plasma THC concentration (Cmax) ranged between 3.2 and 5.5 ng/mL. Differences between products in plasma THC concentration during the first 20–30 min were detected (p = 0.019). Relations were identified between body composition and pharmacokinetic parameters for some products; however, none of these body composition characteristics were consistently related to pharmacokinetics across all five of the products. Edible marijuana had no effect on oral glucose tolerance compared with a marijuana-free control (Matsuda Index; p > 0.395). Commercially available edible marijuana products evoke different plasma THC concentrations shortly after ingestion, but do not appear to influence acute glucose regulation. These data may allow recreational marijuana users to make informed decisions pertaining to rates of edible marijuana ingestion and avoid overdose.
In light of the many demands competing for our attention in today’s modern lifestyle, scheduling healthy behaviors, such as daily exercise, at or around the same time of day can be difficult. Accordingly, the purpose of this study was to compare the endurance benefits of short‐term sprint interval training (SIT) when SIT was completed at a constant or variable time of day. The influence of the time of day of assessment relative to the time of day of training was also examined. SIT consisted of six sessions of 4‐to‐7 x 30‐second sprints on a stationary cycle ergometer completed over two weeks. Endurance exercise performance was assessed via a laboratory‐based cycle ergometer time trial equivalent to 10‐km. Two habituation time trials were completed prior to pre‐SIT assessment. Twenty healthy adults (age: 23 ± 7 years, body mass index: 24.7 ± 3.0 kg/m2, maximal oxygen uptake: 44 ± 9 ml/kg/min (mean ± SD)) were randomly assigned to one of two training conditions: (1) Constant (6 males, 3 females), in which all training and pre/post time‐trials occurred at a fixed time of day that was not necessarily the same time for each participant; or, (2) Variable (7 males, 4 females), in which all training was scheduled such that each session never occurred within 6‐hours of the time of day of the previous session; post‐SIT time trials for the Variable group were completed at the same time of day as pre‐SIT time trials. A second post‐SIT time trial (Post2) was scheduled for all participants to occur at a time of day a minimum of 6‐hours earlier/later than the time of day of the first post‐SIT time trial. SIT improved time trial performance (main effect P=0.019) but only when the time trial did not occur at the same time of day as training (i.e. Post2); the magnitude of improvement was not influenced by whether the training was completed at a constant or variable time of day (Constant: Pre 1153 ± 173, Post 1136 ± 179, & Post2 1123 ± 154 s vs. Variable: Pre 1186 ± 159, Post 1166 ± 158, & Post2 1149 ± 130 s; group x training interaction P=0.646). SIT did not influence body mass or composition, as determined by dual energy X‐ray absorptiometry (all P>0.34). At the start of each SIT session, oral temperature was measured. The co‐efficient of variation appeared lower for the Constant compared with the Variable group (0.6 ± 0.3 vs. 1.1 ± 0.7%; P=0.099). Our preliminary data suggest that SIT improves endurance exercise performance when assessed at a variable time of day, irrespective of whether training is scheduled at a constant or variable time of day. From a public health perspective, scheduling regular exercise at or around the same time of day does not appear to be important for obtaining endurance benefits.
The purpose of the study was to describe and compare the pharmacokinetics of five commercial edible marijuana products, determine the influence of body composition on pharmacokinetics, and, in light of epidemiology suggesting marijuana may offer diabetes protection, explore the influence of edible marijuana on glucose tolerance. Seven regular users of marijuana self-administered five edible products in a randomized crossover design; each product contained 10mg of delta-9-tetrahydrocannabinol (THC). 30-minutes following marijuana ingestion, participants imbibed a 75g glucose beverage. Time-to-peak plasma THC concentration ranged between 35 and 90 minutes; maximal plasma THC concentration (Cmax) ranged between 3.2 and 5.5 ng/mL. Differences between products in plasma THC concentration during the first 20-to-30 minutes were detected (P=0.019). Relations were identified between body composition and pharmacokinetic parameters for some products; however, none of these body composition characteristics were consistently related to pharmacokinetics across all five of the products. Edible marijuana had no effect on oral glucose tolerance compared with a marijuana-free control (Matsuda Index; P>0.395). Commercially available edible marijuana products evoke different plasma THC concentrations shortly after ingestion, but do not appear to influence acute glucose regulation. These data may allow marijuana users to make informed decisions pertaining to rates of edible marijuana ingestion and avoid overdose.
Metformin is the current gold-standard drug for treatment of Diabetes mellitus Type 21 and prescribed at annual quantities of more than 1100 t within Germany.2, 3 It is not metabolized by the human body and only partially degraded during biological wastewater treatment.4 As an environmental pollutant of anthropogenic origin, metformin is present in the range of several hundred ng/L up to one µg/L in most surface waters.5, 6, 7. The production of drinking water from surface waters containing metformin is expected to lead to the formation of disinfection byproducts during chlorine treatment. Scheurer et al. reported that aqueous solutions of metformin rapidly develop an intensive yellow colour upon treatment with sodium hypochlorite (NaOCl; Figure 1).8 Investigations on the chemical reactions taking place during the transformation of metformin by NaOCl led to the discovery of two transformation products Y and C, which are specifically formed during the chlorination of metformin. The primary yellow transformation product Y is a cyclic triazole-derivate with an absorption maximum at 385 nm, carrying an active chlorimino-moiety. It undergoes slow decomposition into the chloroorganic nitrile C, a secondary colourless and stable transformation product.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.